Hims & Hers launches weight-management services in Germany as revenue rises 38%
Key Facts
Hims & Hers has launched its Hims brand services in Germany, starting with weight-management care for men, according to a company announcement expanding the brand's presence within its international operations. The company said in the announcement that Hims was entering Germany to provide "comprehensive weight-management care for millions of men," identifying the initial focus of its services in the German market. The brand launch follows the group's expansion through acquisitions of healthcare platforms with operations outside the United States, including Zava and Eucalyptus. The company's moves combine bringing those platforms into the group with offering services under the Hims and Hers brands in international markets. These moves include Germany and Australia, alongside plans to expand into Canada that the company announced after completing one of its European deals.
The company had confirmed the completion of its Zava acquisition in its statement on plans to enter Canada, saying that move followed the recent closing of the platform's purchase. When the acquisition was announced, Zava served more than 1.3 million active customers, according to Hims & Hers' statement on the deal. The platform's in-house medical team provided about 2.3 million consultations during 2024, a measure of medical activity the company cited in its overview of Zava's operations. The platform operated in Britain, Germany, France and Ireland, bringing the German market within the group's footprint through the acquisition before the Hims launch there. The German announcement thus adds a presence for the brand itself in a market already covered by the acquired platform's operations, as part of the company's European expansion.
In another move to expand its international operations, Hims & Hers announced the completion of its Eucalyptus acquisition, as part of an expansion that also includes Germany. That deal was also linked to the launch of the Hers brand in Australia, where the brand's introduction was based on a women's health platform belonging to the acquired company. The group said the Australian launch represented the rebranding of Eucalyptus-owned Juniper as Hers. This move differs from the German announcement in terms of the brand and target audience: the Australian launch concerns women's health, while Hims is starting in Germany with weight management for men. The two moves bring both brands into the group's international expansion, using an existing platform in Australia and announcing the start of Hims services in Germany.
On medical oversight, the company said prescribing decisions within the German service are made by a professional licensed in the European Union. It expressed that commitment in its announcement by saying that "every prescribing decision is made by a professional licensed in the European Union," as part of its introduction of the weight-management service. The group had appointed Kuldeep Garcha as medical director for Britain, Europe, the Middle East and Africa, in a move concerning its local medical leadership in those markets. According to the appointment statement, Garcha oversees clinical quality and patient safety, two areas of responsibility the company identified for the role. His remit also includes prescribing standards across Britain, Europe, the Middle East and Africa, as the group expands its presence and services outside the U.S. market.
In the United States, Hims & Hers announced a shift in its weight-management business strategy toward approved drug options. It said it would stop advertising compounded glucagon-like peptide-1 drugs on its platform and in its marketing activities. The company defined the scope of the move by saying it would "no longer advertise compounded preparations" through those two channels, in its statement on the strategic shift in its U.S. business. On the group's financial performance, revenue reached about $753 million in the second quarter of 2026, according to its earnings statement. That represented an increase of 38% from the same quarter a year earlier, the year-on-year comparison the company reported for the period's revenue.
Hims & Hers expects revenue for the current fiscal year to range between $3.1 billion and $3.3 billion, according to the guidance in its second-quarter earnings statement. That range covers the group's annual revenue as it pursues its international moves and changes its U.S. weight-management strategy. Its next announced financial milestone is its third-quarter 2026 results, for which the company set a release date in an investor statement. It said the announcement would come after the market close on Monday, November 9, 2026, reporting results for the period following the second quarter. The next disclosure is therefore scheduled after the announcement of the start of Hims services in Germany, and against the backdrop of the group's annual guidance for its business.